Fosamax 70 mg – DIN 02245329
Fosamax is Alendronate 70 mg (tablet), sold in Canada. It is used for osteoporosis (weak bones). It is supplied by Organon Canada Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Alendronate 70 mg
- Brand
- Fosamax
- Strength
- 70 mg
- Used for
- Osteoporosis (weak bones)
- Form
- Tablet
- Manufacturer
- Organon Canada Inc
- Drug class
- Bone medicine (bisphosphonate)
- Sold in
- Canada
- DIN
- 02245329
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Alendronate used for?
Alendronate is used for osteoporosis (weak bones).
- Medicine type
- Bone medicine (bisphosphonate)
Official uses from the US prescribing label
Treatment of Osteoporosis in Postmenopausal Women
Alendronate sodium tablets, USP are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate sodium tablets, USP increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures).
Prevention of Osteoporosis in Postmenopausal Women
Alendronate sodium tablets, USP are indicated for the prevention of postmenopausal osteoporosis.
Treatment to Increase Bone Mass in Men with Osteoporosis
Alendronate sodium tablets, USP are indicated for treatment to increase bone mass in men with osteoporosis.
Treatment of Glucocorticoid-Induced Osteoporosis
Alendronate sodium tablets, USP are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density.
Treatment of Paget's Disease of Bone
Alendronate sodium tablets, USP are indicated for the treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.
Important Limitations of Use
The optimal duration of use has not been determined. The safety and effectiveness of alendronate sodium for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
From the FDA-approved label on DailyMed (published Jul 06, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02245329.
- It names Fosamax, Alendronate 70 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Fosamax by Organon Canada Inc..
In Canada: prescription only.
Ingredients
Active: Alendronic Acid (Alendronate Sodium)
Other Alendronate pills
- MRK 936 Alendronate Sodium 10 mg White, oval, 11 mm Used for osteoporosis (weak bones)
- 93 5141 Alendronate Sodium 10 mg White, round, 8 mm Used for osteoporosis (weak bones)
- F 18 Alendronate Sodium 10 mg White, round, 5 mm Used for osteoporosis (weak bones)
- 10 Alendronate 10 mg White, oval Used for osteoporosis (weak bones)
- F 18 Alendronate 10 mg White, round Used for osteoporosis (weak bones)
- 77 Alendronate Sodium 35 mg White, oval, 10 mm Used for osteoporosis (weak bones)
- WPI 3171 Alendronate Sodium 35 mg White, capsule, 4 mm Used for osteoporosis (weak bones)
- 93 5172 Alendronate Sodium 35 mg White, square, 7 mm Used for osteoporosis (weak bones)